soul trial oral semaglutide cardiovascular outcomes nejm 2025 results New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Cardiovascular risk reduction with once-weekly

O = Reduction in composite CV events (MACE) and their individual components

How People in Maryland Are Using It Although not FDA-approved, some individuals in Maryland are exploring BPC-157 through functional medicine or peptide-focused practices

a single skipped week is not the problem, but chronic gaps are

We use a fine needle to inject VOLUMA XC into the areas of your cheeks that need volume, resulting in immediate lifting and contouring

Boosts Mood Green coffee bean could help improve your mood

While Wegovy is generally well-tolerated, some patients may experience gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation